Allergan comments on first quarter.

IRVINE, Calif.--(BUSINESS WIRE)--Feb. 12, 1996--Allergan Inc. (NYSE:AGN) stated today that weather related declines in cataract surgical procedures coupled with the initiation of a limited, voluntary recall of certain AMO intraocular lenses will have an impact on first quarter 1996 operating results. However total company sales are still expected to be in double digit growth.

William C. Shepherd, chairman and chief executive officer, said, "We are optimistic about our prospects for the remainder of the year. Barring a worsening of these conditions, we anticipate that our surgical business will return to prior trends after the first quarter." Actual results for the quarter and the year will depend upon the reaction to the recall, as well as other factors effecting our businesses such as competitive conditions, the approval and performance of new products, contributions from recently acquired businesses, and the results of geographic expansion efforts.

Physicians have been notified of a limited, voluntary recall of certain AMO PhacoFlex II Model SI-30NB intraocular lenses and advised that intensive, scientific investigation to date have concluded that these lenses pose no safety or efficacy issues. No adverse events have been reported.

Allergan Inc., a global health care company headquartered in Irvine, Calif., develops, manufactures, and markets specialty therapeutic products for eye and skin care and neuromuscular disorders. A technology-driven company, Allergen is working to be the partner of choice for ever better specialty health care.

CONTACT: Allergan Inc.

Jeff D'Eliscu, 714/246-4636